What's Coming Next

Reading the next few years without the hype

If you spend any time in mom groups, you have seen the breathless posts: a pill that beats the shot, a drug that melts twice as much, the “Ozempic killer.” Most of it is investor chatter dressed up as health news. But underneath the noise is a genuinely busy pipeline, and a mother deciding whether to start now or wait deserves the real trial numbers, not the headlines. Here is what is actually coming, in plain language, with the data attached. One caveat to hold throughout: these trials were run in adults with obesity or diabetes, generally not in pregnant or breastfeeding women, so “what's coming” is about options, not a green light for every situation.

The one everyone's waiting for: a real pill

The single biggest shift on the horizon is oral. Injections are a barrier for a lot of busy mothers, and two different pills are closing the gap. The furthest along in a familiar molecule is high-dose oral semaglutide — the same drug as Wegovy and Ozempic, in tablet form. In its OASIS 1 trial, a once-daily 50 mg tablet produced about 15% weight loss over 68 weeks in adults with obesity, versus roughly 2% on placebo¹ — numbers that sit right alongside the semaglutide injection.

The more disruptive pill is orforglipron, a small-molecule GLP-1 that, unlike oral semaglutide, has no food-and-water timing rules and is far easier to manufacture at scale. In its phase 3 obesity trial, the 36 mg dose delivered about an 11% average reduction in body weight at 72 weeks². That is a notch below the strongest injectables, but a genuinely convenient daily pill with no injection and no fasting window is a different kind of product for a mother's actual life — which is exactly why the no-injection question matters as much as the raw percentage.

For a lot of mothers the real breakthrough is not a bigger number — it is a pill you can take without a needle, a fasting window, or a second thought.

The heavy hitters: stacking more hormones

The other frontier is not about delivery but about power, achieved by combining hormones. Today's strongest approved drug, tirzepatide, already pairs two gut hormones and reached roughly 21% weight loss in its pivotal trial³. The next generation stacks more.

Retatrutide adds a third hormone (a “triple agonist”). In its phase 2 trial, the highest dose produced a striking average weight reduction of about 24% at 48 weeks⁴ — the largest figures the field has seen from a medication, though phase 2 results still need confirmation in the larger phase 3 program underway. CagriSema takes a different route, combining semaglutide with a second hormone called an amylin analogue; in a phase 3 trial in adults with type 2 diabetes it reduced body weight by about 14% while sharply improving blood sugar⁵. Diabetes trials tend to show smaller weight numbers than obesity trials, so read that figure in context.

What this means for a mother deciding today

So should you wait? Usually not for its own sake. The best drug is the one you can actually get, afford, and stay on — and the approved options today are already highly effective. The pipeline mostly changes the odds that, a year or two out, there will be a more convenient pill or a more powerful combination, likely at a similar or better price as competition grows. That is a reason for optimism, not paralysis. If cost is the thing holding you back, the smarter move is to understand today's real prices and the cheapest legitimate routes rather than waiting on a launch that may be years and a coverage fight away.

If you do want to start now, use a program that will let you switch as the field evolves rather than locking you in; in our provider reporting, CoreAge Rx rates first for exactly that kind of flexible, transparent access, and our complete 2026 guide for moms walks through the rest. This explainer is educational only and not medical advice; drug availability, approvals, and labeling change, and none of these agents is established as safe in pregnancy or breastfeeding — always confirm current status with a clinician.